TABLE 2

Efavirenz pharmacokinetic parameter in HIV-infected children with and without tuberculosis (TB) coinfection expressed as geometric mean and 95% confidence interval

ParametercTB/HIVd
All (n = 105)HIV (n = 62)On ATT (n = 43)Off ATT (n = 40)P valueaP valueb
Tmax (h)2.8 (2.5 – 3.2)2.7 (2.3 – 3.1)3.0 (2.5 – 3.7)2.4 (2.1 – 2.8)0.3420.302
Cmax (mg/liter)4.0 (3.6 – 4.5)4.2 (93.6 – 4.8)3.9 (3.2 – 4.6)3.3 (2.7 – 4.1)0.5320.060
C12h (mg/liter)2.3 (2.0 – 2.6)2.3 (1.9 – 2.7)2.2 (1.7 – 2.8)1.6 (1.3 – 2.1)0.7270.017
Cmin (mg/liter)1.7 (1.4 – 2.1)1.9 (1.6 – 2.3)1.5 (1.0 – 2.1)1.0 (0.7 – 1.5)0.2300.005
AUC0–24h (mg · h/liter)59.0 (51.9 – 67.2)60.9 (51.8 – 71.5)56.47 (45.3 – 70.5)45.0 (35.8 – 56.6)0.5750.028
CL/F (liter/h)4.7 (4.1 – 5.3)4.7 (4.0 – 5.5)4.7 (3.7 – 5.8)6.2 (4.9 – 7.8)0.9420.044
V/F (liter)141.5 (123.1 – 162.6)146.3 (125.4 – 170.6)134.8 (103.4 – 175.8)175.2 (140.0 – 219.3)0.5950.171
t1/2 (h)21.0 (18.1 – 24.3)21.6 (18.8 – 24.8)20.1 (14.8 – 27.3)19.2 (16.0 – 23.0)0.6690.297
  • a P value for HIV versus TB/HIV on TB therapy.

  • b P value for HIV versus TB/HIV off TB therapy.

  • c AUC0–24h, total area under the curve from time 0 to 24 h; C12h, concentration at 12 h postdose; CL/F, apparent oral clearance; Cmax, peak concentration; Cmin, minimum concentration; t1/2, half-life; Tmax, time to Cmax; V/F, apparent volume of distribution.

  • d ATT, antituberculosis therapy.